ESCRS - ESCRS marketing competition

ESCRS marketing competition

The deadline for the ESCRS Practice Marketing Competition is Monday 30 July 2018

ESCRS marketing competition
Colin Kerr
Colin Kerr
Published: Tuesday, May 1, 2018
Paul Rosen
The deadline for the ESCRS Practice Marketing Competition is Monday 30 July 2018. The winner will be announced during the 36th Congress of the ESCRS in Vienna. “The competition is an opportunity for ophthalmologists to make a contribution to the Practice Management and Development Programme,” said Paul Rosen, chair of the Committee. “The competition enables ESCRS members to demonstrate what they have achieved with their entrepreneurial skills and show colleagues what they may be able to do in their own businesses.” For more information visit: http://www.escrs.org/vienna2018/
Tags: ESCRS, marketing
Latest Articles
Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

Read more...

Diamonds in the Rough

The push for inclusivity in ophthalmology.

Read more...

Making Female Leadership More than a Moment

A remarkable global confluence of women in key positions.

Read more...

ESCRS Talks Technology at AAO

Europe adopts technological advances, US still waiting for lenses and lasers.

Read more...

Sorting Out Simultaneous Vision IOLs

The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.

Read more...

Big Advantages to Small-Aperture IOLs

Small-aperture IOLs offer superior image quality with increased range of focus.

Read more...

Prioritising Self-Care

Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.

Read more...

Valuing Clinical Trial Design

How inclusivity and diversity can enhance scientific accuracy in research.

Read more...

Knowing Iris Repair: Using Iridodiathermy in Iris Surgery

Prepare for decentred pupils and uneven irides in multiple situations.

Read more...

Neuroprotectant Treatment for MacTel Type 2

Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.

Read more...